Log in

Ionis Pharmaceuticals Price Target & Analyst Ratings (NASDAQ:IONS)

+0.82 (+1.28 %)
(As of 12/6/2019 08:52 AM ET)
Today's Range
Now: $65.00
50-Day Range
MA: $58.31
52-Week Range
Now: $65.00
Volume883,858 shs
Average Volume1.13 million shs
Market Capitalization$9.14 billion
P/E Ratio21.96
Dividend YieldN/A

Analyst Ratings

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Ionis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $76.60, suggesting that the stock has a possible upside of 17.85%. The high price target for IONS is $120.00 and the low price target for IONS is $48.00. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.422.362.132.00
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $76.60$76.60$67.25$64.38
Price Target Upside: 17.85% upside35.89% upside1.54% downside0.53% downside

Ionis Pharmaceuticals (NASDAQ:IONS) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ionis Pharmaceuticals (NASDAQ:IONS) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2019William BlairInitiated CoverageMarket PerformLow
11/13/2019Bank of AmericaInitiated CoverageBuy$70.00Medium
11/7/2019Piper Jaffray CompaniesLower Price TargetNeutral$75.00 ➝ $70.00Medium
11/7/2019Needham & Company LLCReiterated RatingBuy$87.00Low
11/7/2019Morgan StanleyDowngradeEqual ➝ Weight$63.00 ➝ $48.00Low
11/7/2019CowenReiterated RatingHoldLow
10/15/2019Cantor FitzgeraldSet Price TargetHold$65.00N/A
10/10/2019Wells Fargo & CoBoost Price TargetOutperform$90.00 ➝ $120.00Medium
9/10/2019Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$80.00High
8/7/2019Evercore ISISet Price TargetHold$76.00Low
7/24/2019BMO Capital MarketsLower Price TargetOutperform$96.00 ➝ $95.00Low
3/18/2019JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$47.00 ➝ $55.00Low
11/27/2018Leerink SwannInitiated CoverageMarket Perform$50.00High
9/25/2018Stifel NicolausBoost Price TargetHold ➝ Hold$45.00 ➝ $48.00High
6/20/2018BarclaysDowngradeEqual Weight ➝ Underweight$52.00High
(Data available from 12/6/2017 forward)
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: What is the LIBOR?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel